JOURNAL OF CLINICAL INVESTIGATION-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2158258, encodeId=7db5215825844, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿8天还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b14f2074305, createdName=1521f0cae7m, createdTime=Mon Sep 18 10:40:18 CST 2023, time=2023-09-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123097, encodeId=a305212309efa, content=偏重的研究方向：免疫;肿瘤;分子机制 经验分享：记录一下我的投稿经历，给各位战友作为参考。3/31/23投出，4/1变为under consideration by editorial board , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Sat Apr 01 09:00:08 CST 2023, time=2023-04-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149210, encodeId=d12e21492108e, content=有人投过nhanes这种公共数据库的文章吗，接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9238380092, createdName=ms4000000552232072, createdTime=Fri Jul 21 22:16:49 CST 2023, time=2023-07-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2098655, encodeId=798a209865500, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床结果;临床各科 经验分享：接受与临床密切相关的文章，比如基因拷贝数变异，单核苷酸多态性，基因突变以及甲基化相关的论文。主要看中其中的临床意义，接收观点新异的文章，不着重机制的探讨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:17:15 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231472, encodeId=648112314e268, content=6.25投稿，目前还在under consideration by editorial board，焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Sat Jul 09 11:35:57 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125930, encodeId=69892125930ed, content=3月27投的，后来一直是 Under consideration by Editorial Board,现在都快20天了，为啥还不拒我啊。烦死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Fri Apr 14 16:19:29 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1228461, encodeId=fadf1228461c7, content=昨天投稿，今天In external peer review，期待有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f626155627, createdName=ms9000002079915779, createdTime=Fri Jun 24 16:14:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊)]

2023-10-04 ms1000000589600011 来自瑞典

审稿速度:2.0
偏重的研究方向：免疫;肿瘤
经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验

70 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2158258, encodeId=7db5215825844, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿8天还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b14f2074305, createdName=1521f0cae7m, createdTime=Mon Sep 18 10:40:18 CST 2023, time=2023-09-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123097, encodeId=a305212309efa, content=偏重的研究方向：免疫;肿瘤;分子机制 经验分享：记录一下我的投稿经历，给各位战友作为参考。3/31/23投出，4/1变为under consideration by editorial board , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Sat Apr 01 09:00:08 CST 2023, time=2023-04-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149210, encodeId=d12e21492108e, content=有人投过nhanes这种公共数据库的文章吗，接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9238380092, createdName=ms4000000552232072, createdTime=Fri Jul 21 22:16:49 CST 2023, time=2023-07-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2098655, encodeId=798a209865500, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床结果;临床各科 经验分享：接受与临床密切相关的文章，比如基因拷贝数变异，单核苷酸多态性，基因突变以及甲基化相关的论文。主要看中其中的临床意义，接收观点新异的文章，不着重机制的探讨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:17:15 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231472, encodeId=648112314e268, content=6.25投稿，目前还在under consideration by editorial board，焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Sat Jul 09 11:35:57 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125930, encodeId=69892125930ed, content=3月27投的，后来一直是 Under consideration by Editorial Board,现在都快20天了，为啥还不拒我啊。烦死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Fri Apr 14 16:19:29 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1228461, encodeId=fadf1228461c7, content=昨天投稿，今天In external peer review，期待有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f626155627, createdName=ms9000002079915779, createdTime=Fri Jun 24 16:14:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊)]

2023-09-18 1521f0cae7m 来自上海

审稿速度:1.0 | 投稿命中率:25.0
经验分享：投稿8天还没外审

55 0

[GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2158258, encodeId=7db5215825844, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿8天还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b14f2074305, createdName=1521f0cae7m, createdTime=Mon Sep 18 10:40:18 CST 2023, time=2023-09-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123097, encodeId=a305212309efa, content=偏重的研究方向：免疫;肿瘤;分子机制 经验分享：记录一下我的投稿经历，给各位战友作为参考。3/31/23投出，4/1变为under consideration by editorial board , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Sat Apr 01 09:00:08 CST 2023, time=2023-04-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149210, encodeId=d12e21492108e, content=有人投过nhanes这种公共数据库的文章吗，接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9238380092, createdName=ms4000000552232072, createdTime=Fri Jul 21 22:16:49 CST 2023, time=2023-07-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2098655, encodeId=798a209865500, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床结果;临床各科 经验分享：接受与临床密切相关的文章，比如基因拷贝数变异，单核苷酸多态性，基因突变以及甲基化相关的论文。主要看中其中的临床意义，接收观点新异的文章，不着重机制的探讨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:17:15 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231472, encodeId=648112314e268, content=6.25投稿，目前还在under consideration by editorial board，焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Sat Jul 09 11:35:57 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125930, encodeId=69892125930ed, content=3月27投的，后来一直是 Under consideration by Editorial Board,现在都快20天了，为啥还不拒我啊。烦死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Fri Apr 14 16:19:29 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1228461, encodeId=fadf1228461c7, content=昨天投稿，今天In external peer review，期待有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f626155627, createdName=ms9000002079915779, createdTime=Fri Jun 24 16:14:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊)]

2023-04-01 ms7000001335611101 来自天津

偏重的研究方向：免疫;肿瘤;分子机制
经验分享：记录一下我的投稿经历，给各位战友作为参考。3/31/23投出，4/1变为under consideration by editorial board

100 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2158258, encodeId=7db5215825844, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿8天还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b14f2074305, createdName=1521f0cae7m, createdTime=Mon Sep 18 10:40:18 CST 2023, time=2023-09-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123097, encodeId=a305212309efa, content=偏重的研究方向：免疫;肿瘤;分子机制 经验分享：记录一下我的投稿经历，给各位战友作为参考。3/31/23投出，4/1变为under consideration by editorial board , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Sat Apr 01 09:00:08 CST 2023, time=2023-04-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149210, encodeId=d12e21492108e, content=有人投过nhanes这种公共数据库的文章吗，接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9238380092, createdName=ms4000000552232072, createdTime=Fri Jul 21 22:16:49 CST 2023, time=2023-07-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2098655, encodeId=798a209865500, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床结果;临床各科 经验分享：接受与临床密切相关的文章，比如基因拷贝数变异，单核苷酸多态性，基因突变以及甲基化相关的论文。主要看中其中的临床意义，接收观点新异的文章，不着重机制的探讨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:17:15 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231472, encodeId=648112314e268, content=6.25投稿，目前还在under consideration by editorial board，焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Sat Jul 09 11:35:57 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125930, encodeId=69892125930ed, content=3月27投的，后来一直是 Under consideration by Editorial Board,现在都快20天了，为啥还不拒我啊。烦死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Fri Apr 14 16:19:29 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1228461, encodeId=fadf1228461c7, content=昨天投稿，今天In external peer review，期待有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f626155627, createdName=ms9000002079915779, createdTime=Fri Jun 24 16:14:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊)]

2023-03-02 12cea5a4m34暂无昵称来自广东省

请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~

100 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2158258, encodeId=7db5215825844, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿8天还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b14f2074305, createdName=1521f0cae7m, createdTime=Mon Sep 18 10:40:18 CST 2023, time=2023-09-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123097, encodeId=a305212309efa, content=偏重的研究方向：免疫;肿瘤;分子机制 经验分享：记录一下我的投稿经历，给各位战友作为参考。3/31/23投出，4/1变为under consideration by editorial board , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Sat Apr 01 09:00:08 CST 2023, time=2023-04-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149210, encodeId=d12e21492108e, content=有人投过nhanes这种公共数据库的文章吗，接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9238380092, createdName=ms4000000552232072, createdTime=Fri Jul 21 22:16:49 CST 2023, time=2023-07-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2098655, encodeId=798a209865500, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床结果;临床各科 经验分享：接受与临床密切相关的文章，比如基因拷贝数变异，单核苷酸多态性，基因突变以及甲基化相关的论文。主要看中其中的临床意义，接收观点新异的文章，不着重机制的探讨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:17:15 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231472, encodeId=648112314e268, content=6.25投稿，目前还在under consideration by editorial board，焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Sat Jul 09 11:35:57 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125930, encodeId=69892125930ed, content=3月27投的，后来一直是 Under consideration by Editorial Board,现在都快20天了，为啥还不拒我啊。烦死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Fri Apr 14 16:19:29 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1228461, encodeId=fadf1228461c7, content=昨天投稿，今天In external peer review，期待有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f626155627, createdName=ms9000002079915779, createdTime=Fri Jun 24 16:14:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊)]

2023-07-21 ms4000000552232072 来自北京

有人投过nhanes这种公共数据库的文章吗，接收吗

56 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2158258, encodeId=7db5215825844, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿8天还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b14f2074305, createdName=1521f0cae7m, createdTime=Mon Sep 18 10:40:18 CST 2023, time=2023-09-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123097, encodeId=a305212309efa, content=偏重的研究方向：免疫;肿瘤;分子机制 经验分享：记录一下我的投稿经历，给各位战友作为参考。3/31/23投出，4/1变为under consideration by editorial board , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Sat Apr 01 09:00:08 CST 2023, time=2023-04-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149210, encodeId=d12e21492108e, content=有人投过nhanes这种公共数据库的文章吗，接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9238380092, createdName=ms4000000552232072, createdTime=Fri Jul 21 22:16:49 CST 2023, time=2023-07-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2098655, encodeId=798a209865500, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床结果;临床各科 经验分享：接受与临床密切相关的文章，比如基因拷贝数变异，单核苷酸多态性，基因突变以及甲基化相关的论文。主要看中其中的临床意义，接收观点新异的文章，不着重机制的探讨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:17:15 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231472, encodeId=648112314e268, content=6.25投稿，目前还在under consideration by editorial board，焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Sat Jul 09 11:35:57 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125930, encodeId=69892125930ed, content=3月27投的，后来一直是 Under consideration by Editorial Board,现在都快20天了，为啥还不拒我啊。烦死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Fri Apr 14 16:19:29 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1228461, encodeId=fadf1228461c7, content=昨天投稿，今天In external peer review，期待有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f626155627, createdName=ms9000002079915779, createdTime=Fri Jun 24 16:14:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊)]

2022-11-05 slientwo

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：临床结果;临床各科
经验分享：接受与临床密切相关的文章，比如基因拷贝数变异，单核苷酸多态性，基因突变以及甲基化相关的论文。主要看中其中的临床意义，接收观点新异的文章，不着重机制的探讨。

96 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2158258, encodeId=7db5215825844, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿8天还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b14f2074305, createdName=1521f0cae7m, createdTime=Mon Sep 18 10:40:18 CST 2023, time=2023-09-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123097, encodeId=a305212309efa, content=偏重的研究方向：免疫;肿瘤;分子机制 经验分享：记录一下我的投稿经历，给各位战友作为参考。3/31/23投出，4/1变为under consideration by editorial board , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Sat Apr 01 09:00:08 CST 2023, time=2023-04-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149210, encodeId=d12e21492108e, content=有人投过nhanes这种公共数据库的文章吗，接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9238380092, createdName=ms4000000552232072, createdTime=Fri Jul 21 22:16:49 CST 2023, time=2023-07-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2098655, encodeId=798a209865500, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床结果;临床各科 经验分享：接受与临床密切相关的文章，比如基因拷贝数变异，单核苷酸多态性，基因突变以及甲基化相关的论文。主要看中其中的临床意义，接收观点新异的文章，不着重机制的探讨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:17:15 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231472, encodeId=648112314e268, content=6.25投稿，目前还在under consideration by editorial board，焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Sat Jul 09 11:35:57 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125930, encodeId=69892125930ed, content=3月27投的，后来一直是 Under consideration by Editorial Board,现在都快20天了，为啥还不拒我啊。烦死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Fri Apr 14 16:19:29 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1228461, encodeId=fadf1228461c7, content=昨天投稿，今天In external peer review，期待有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f626155627, createdName=ms9000002079915779, createdTime=Fri Jun 24 16:14:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊)]

2022-07-09 ms8000001656880339

6.25投稿，目前还在under consideration by editorial board，焦虑

109 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2158258, encodeId=7db5215825844, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿8天还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b14f2074305, createdName=1521f0cae7m, createdTime=Mon Sep 18 10:40:18 CST 2023, time=2023-09-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123097, encodeId=a305212309efa, content=偏重的研究方向：免疫;肿瘤;分子机制 经验分享：记录一下我的投稿经历，给各位战友作为参考。3/31/23投出，4/1变为under consideration by editorial board , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Sat Apr 01 09:00:08 CST 2023, time=2023-04-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149210, encodeId=d12e21492108e, content=有人投过nhanes这种公共数据库的文章吗，接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9238380092, createdName=ms4000000552232072, createdTime=Fri Jul 21 22:16:49 CST 2023, time=2023-07-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2098655, encodeId=798a209865500, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床结果;临床各科 经验分享：接受与临床密切相关的文章，比如基因拷贝数变异，单核苷酸多态性，基因突变以及甲基化相关的论文。主要看中其中的临床意义，接收观点新异的文章，不着重机制的探讨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:17:15 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231472, encodeId=648112314e268, content=6.25投稿，目前还在under consideration by editorial board，焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Sat Jul 09 11:35:57 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125930, encodeId=69892125930ed, content=3月27投的，后来一直是 Under consideration by Editorial Board,现在都快20天了，为啥还不拒我啊。烦死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Fri Apr 14 16:19:29 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1228461, encodeId=fadf1228461c7, content=昨天投稿，今天In external peer review，期待有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f626155627, createdName=ms9000002079915779, createdTime=Fri Jun 24 16:14:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊)]

2023-04-14 1243aaabm66暂无昵称来自山东省

3月27投的，后来一直是 Under consideration by Editorial Board,现在都快20天了，为啥还不拒我啊。烦死了

56 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2158258, encodeId=7db5215825844, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿8天还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b14f2074305, createdName=1521f0cae7m, createdTime=Mon Sep 18 10:40:18 CST 2023, time=2023-09-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123097, encodeId=a305212309efa, content=偏重的研究方向：免疫;肿瘤;分子机制 经验分享：记录一下我的投稿经历，给各位战友作为参考。3/31/23投出，4/1变为under consideration by editorial board , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Sat Apr 01 09:00:08 CST 2023, time=2023-04-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149210, encodeId=d12e21492108e, content=有人投过nhanes这种公共数据库的文章吗，接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9238380092, createdName=ms4000000552232072, createdTime=Fri Jul 21 22:16:49 CST 2023, time=2023-07-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2098655, encodeId=798a209865500, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床结果;临床各科 经验分享：接受与临床密切相关的文章，比如基因拷贝数变异，单核苷酸多态性，基因突变以及甲基化相关的论文。主要看中其中的临床意义，接收观点新异的文章，不着重机制的探讨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:17:15 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231472, encodeId=648112314e268, content=6.25投稿，目前还在under consideration by editorial board，焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Sat Jul 09 11:35:57 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125930, encodeId=69892125930ed, content=3月27投的，后来一直是 Under consideration by Editorial Board,现在都快20天了，为啥还不拒我啊。烦死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Fri Apr 14 16:19:29 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1228461, encodeId=fadf1228461c7, content=昨天投稿，今天In external peer review，期待有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f626155627, createdName=ms9000002079915779, createdTime=Fri Jun 24 16:14:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊)]

2022-06-24 ms9000002079915779

昨天投稿，今天In external peer review，期待有个好结果

283 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2158258, encodeId=7db5215825844, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿8天还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b14f2074305, createdName=1521f0cae7m, createdTime=Mon Sep 18 10:40:18 CST 2023, time=2023-09-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123097, encodeId=a305212309efa, content=偏重的研究方向：免疫;肿瘤;分子机制 经验分享：记录一下我的投稿经历，给各位战友作为参考。3/31/23投出，4/1变为under consideration by editorial board , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Sat Apr 01 09:00:08 CST 2023, time=2023-04-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149210, encodeId=d12e21492108e, content=有人投过nhanes这种公共数据库的文章吗，接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9238380092, createdName=ms4000000552232072, createdTime=Fri Jul 21 22:16:49 CST 2023, time=2023-07-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2098655, encodeId=798a209865500, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床结果;临床各科 经验分享：接受与临床密切相关的文章，比如基因拷贝数变异，单核苷酸多态性，基因突变以及甲基化相关的论文。主要看中其中的临床意义，接收观点新异的文章，不着重机制的探讨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:17:15 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231472, encodeId=648112314e268, content=6.25投稿，目前还在under consideration by editorial board，焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Sat Jul 09 11:35:57 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125930, encodeId=69892125930ed, content=3月27投的，后来一直是 Under consideration by Editorial Board,现在都快20天了，为啥还不拒我啊。烦死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4402471427, createdName=1243aaabm66暂无昵称, createdTime=Fri Apr 14 16:19:29 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1228461, encodeId=fadf1228461c7, content=昨天投稿，今天In external peer review，期待有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f626155627, createdName=ms9000002079915779, createdTime=Fri Jun 24 16:14:32 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊)]

2023-02-25 时光若刻来自伊利诺伊

审稿速度:2.0 | 投稿命中率:5.0
经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？

123 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务